This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vaughan, T. L. Articles by Reid, B. J. Search for Related Content PubMed PubMed Citation Articles by Vaughan, T. L. Articles by Reid, B. J.

Nonsteroidal Anti-inflammatory Drug Use, Body Mass Index, and Anthropometry in Relation to Genetic and Flow Cytometric Abnormalities in Barrett’s Esophagus¹

Program in Epidemiology [T. L. V.], Program in Gastrointestinal Oncology [T. L. V., P. L. B., P. C. G., L. J. P., C. A. S., P. S. R., B. J. R.], and Cancer Prevention Research Program [A. R. K.], Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, and Departments of Epidemiology [T. L. V., A. R. K.], Medicine [P. L. B., D. S. L., B. J. R.], Pathology [P. S. R.], and Genetics [B. J. R.], University of Washington, Seattle, Washington 98195

A dramatic increase in the incidence of esophageal adenocarcinoma has occurred among men in the United States over the lasttwo decades. The underlying reasons remain largely unknown, although the increasing prevalence of obesity likely plays a role. Most adenocarcinomas arise in a metaplastic epithelium termed Barrett’s esophagus (BE) that develops in approximately 10% of persons who have chronic gastroesophageal reflux. Persons with BE are at high risk (0.5–1.0%/year) of progressing to cancer. In a cross-sectional study of 429 persons with BE, we evaluated the associations between increased body mass index, anthropometric measures, cigarette smoking, use of nonsteroidal anti-inflammatory drugs (NSAIDs) and markers of increased risk, including aneuploidy, increased 4N fraction, loss of heterozygosity (LOH) of 17p and 9p alleles, and high-grade dysplasia (HGD). In logistic regression models adjusting for age, gender, NSAID use, and cigarette smoking, increasing waist:hip ratio was related to increasing risk of aneuploidy (trend P = 0.01), 17p LOH (trend P = 0.005), and 9p LOH (trend P = 0.007). The odds ratios comparing highest to lowest quartiles were 4.3 [95% confidence interval (CI), 1.2–15.6] for aneuploidy, 3.9 (95% CI, 1.3–11.4) for 17p LOH, and 2.7 (95% CI, 1.2–6.3) for 9p LOH. A nonsignificant trend was also observed for increased 4N fraction, whereas little association was found for HGD. Similar patterns of risk were noted for other anthropometric measures such as waist:thigh and abdomen:thigh ratios. There was no evidence that elevated body mass index increased risk of any of the biomarkers. Suggestive evidence also was found for a protective effect of NSAID use. The odds ratios for current users, compared with those who never used NSAIDs regularly, were 0.6 (95% CI, 0.3–1.4) for increased 4N, 0.6 (95% CI, 0.3–1.3) for aneuploidy, 0.3 (95% CI, 0.1–0.7) for 17p LOH, and 0.7 (95% CI, 0.4–1.2) for HGD. There was no association between NSAID use and risk of 9p LOH. We conclude that an abdominal distribution of body fat, which is more common in men and is termed male-pattern obesity, may be a strong predictor of risk of neoplastic progression among persons with BE and may account in part for the male predominance of BE and esophageal adenocarcinoma. We also conclude that NSAID use may reduce the risk of progression to cancer in this population. Prospective studies are needed to confirm these results.

This article has been cited by other articles:

				S. Sadeghi, C. J. Bain, N. Pandeya, P. M. Webb, A. C. Green, D. C. Whiteman, and for the Australian Cancer Study Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1169 - 1178. [Abstract] [Full Text] [PDF]

				D. A. Corley, A. Kubo, and W. Zhao Abdominal Obesity and the Risk of Esophageal and Gastric Cardia Carcinomas Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 352 - 358. [Abstract] [Full Text] [PDF]

				R. A. Risques, T. L. Vaughan, X. Li, R. D. Odze, P. L. Blount, K. Ayub, J. L. Gallaher, B. J. Reid, and P. S. Rabinovitch Leukocyte Telomere Length Predicts Cancer Risk in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2649 - 2655. [Abstract] [Full Text] [PDF]

				S. H. Siahpush, T. L. Vaughan, J. N. Lampe, R. Freeman, S. Lewis, R. D. Odze, P. L. Blount, K. Ayub, P. S. Rabinovitch, B. J. Reid, et al. Longitudinal Study of Insulin-like Growth Factor, Insulin-like Growth Factor Binding Protein-3, and their Polymorphisms: Risk of Neoplastic Progression in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2387 - 2395. [Abstract] [Full Text] [PDF]

				D. A Corley Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link? Gut, November 1, 2007; 56(11): 1493 - 1494. [Full Text] [PDF]

				J G Williams, S E Roberts, M F Ali, W Y Cheung, D R Cohen, G Demery, A Edwards, M Greer, M D Hellier, H A Hutchings, et al. Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence Gut, February 1, 2007; 56(suppl_1): 1 - 113. [Full Text] [PDF]

				D. L. Chao, C. C. Maley, X. Wu, D. C. Farrow, P. C. Galipeau, C. A. Sanchez, T. G. Paulson, P. S. Rabinovitch, B. J. Reid, M. R. Spitz, et al. Mutagen Sensitivity and Neoplastic Progression in Patients with Barrett's Esophagus: A Prospective Analysis. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1935 - 1940. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				L. A. Anderson, B. T. Johnston, R.G. P. Watson, S. J. Murphy, H. R. Ferguson, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence. Cancer Res., May 1, 2006; 66(9): 4975 - 4982. [Abstract] [Full Text] [PDF]

				A. R. Kristal, P. L. Blount, J. M. Schenk, C. A. Sanchez, P. S. Rabinovitch, R. D. Odze, J. Standley, T. L. Vaughan, and B. J. Reid Low-Fat, High Fruit and Vegetable Diets and Weight Loss Do Not Affect Biomarkers of Cellular Proliferation in Barrett Esophagus Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2377 - 2383. [Abstract] [Full Text] [PDF]

				A. G. Casson, Z. Zheng, S. C. Evans, P. J. Veugelers, G. A. Porter, and D. L. Guernsey Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma Carcinogenesis, September 1, 2005; 26(9): 1536 - 1541. [Abstract] [Full Text] [PDF]

				C. C. Maley, B. J. Reid, and S. Forrest Cancer Prevention Strategies That Address the Evolutionary Dynamics of Neoplastic Cells: Simulating Benign Cell Boosters and Selection for Chemosensitivity Cancer Epidemiol. Biomarkers Prev., August 1, 2004; 13(8): 1375 - 1384. [Abstract] [Full Text] [PDF]

				M. D. Gammon, M. B. Terry, N. Arber, W.-H. Chow, H. A. Risch, T. L. Vaughan, J. B. Schoenberg, S. T. Mayne, J. L. Stanford, R. Dubrow, et al. Nonsteroidal Anti-inflammatory Drug Use Associated with Reduced Incidence of Adenocarcinomas of the Esophagus and Gastric Cardia that Overexpress Cyclin D1: A Population-Based Study Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 34 - 39. [Abstract] [Full Text] [PDF]